Apis Capital Advisors LLC lowered its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH – Free Report) by 44.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,000 shares of the company’s stock after selling 110,000 shares during the period. Apis Capital Advisors LLC’s holdings in Delcath Systems were worth $1,374,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of DCTH. Nantahala Capital Management LLC acquired a new position in shares of Delcath Systems during the third quarter worth $7,164,000. Marshall Wace LLP acquired a new position in Delcath Systems in the second quarter valued at $6,572,000. Divisadero Street Capital Management LP acquired a new position in Delcath Systems in the third quarter valued at $5,119,000. Rosalind Advisors Inc. boosted its stake in Delcath Systems by 13.8% in the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after acquiring an additional 315,583 shares in the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.
Delcath Systems Price Performance
DCTH stock opened at $11.93 on Thursday. The company’s 50 day simple moving average is $10.95 and its 200-day simple moving average is $10.18. The firm has a market capitalization of $411.82 million, a PE ratio of 1,193.00 and a beta of 0.54. Delcath Systems, Inc. has a 12 month low of $8.12 and a 12 month high of $14.62.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on DCTH shares. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Evercore set a $27.00 price objective on shares of Delcath Systems in a research note on Thursday, February 26th. BTIG Research decreased their price objective on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Zacks Research cut shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Finally, Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Delcath Systems has an average rating of “Hold” and a consensus target price of $22.50.
Read Our Latest Analysis on DCTH
About Delcath Systems
Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.
Featured Stories
- Five stocks we like better than Delcath Systems
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding DCTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Delcath Systems, Inc. (NASDAQ:DCTH – Free Report).
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
